Roche’s Gazyva shows strong phase III results for treatment of idiopathic nephrotic syndrome
Key secondary endpoints also demonstrated statistically significant and clinically meaningful benefits with Gazyva
Key secondary endpoints also demonstrated statistically significant and clinically meaningful benefits with Gazyva
Sotyktu continues to demonstrate consistent efficacy and safety across rheumatic conditions
Allergan Aesthetics reaffirms commitment to empowering girls through STEM mentorship and education initiatives
The Fast Track Designation was supported by nonclinical data as well as clinical results from the ongoing Phase I/IIa trial evaluating the safety and tolerability
Advancing toward Phase 2a evaluation in chemotherapy-related pain, a condition with no approved treatments and potential for FDA Fast Track designation
It will produce a comprehensive range of dosage forms including tablets, hard gelatin capsules, liquids, injectables, topicals, and beta-lactam products
Sigachi Industries has reported total income of Rs. 112.97 crore during the period ended September 30, 2025
Dr Reddys Laboratories has reported total income of Rs. 8,805.1 crore during the period ended September 30, 2025
The company's net income attributable to equity holders dropped to €2.80 billion from €2.82 billion last year
Telangana aims to increase the value of the Life Sciences economy from US$ 80 billion to US$ 250 billion by 2030
Subscribe To Our Newsletter & Stay Updated